Economic evaluation of high vs low dosage lisinopril in patients with chronic heart failure;Valutazione economica della terapia con lisinopril ad alto verso basso dossaggio nel trattamento dei soggetti con scompenso cardiaco cronico

PharmacoEconomics - Italian Research Articles

Volumn 4, Issue 2, 2002, Pages 45-55

  Scalone, L ^a   Mantovani, L G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LISINOPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DRUG COST; DRUG MARKETING; DRUG MEGADOSE; ECONOMIC EVALUATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL COST; HUMAN; HYPOTHESIS; ITALY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NATIONAL HEALTH SERVICE;

EID: 0036400043     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320594     Document Type: Article

References (40)

1. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure. A population-based study. Eur Heart J 1999; 20:421-8
2. The SEOSI Investigators. Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. Eur Heart J 1997; 18: 1457-64
3. Misuraca G, Serafini O, Caporale R, et al. Prevalenza e caratteristiche cliniche dell'insufficienza cardiaca in un campione di popolazione della Calabria. G Ital Cardiol 1998; 28: 1385-90
4. Stafford RS, Saglam D, Blumenthal D. National patterns of Angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460-4
5. McMurray JJ, Steward S. Heart Failure. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596-602
6. Albanese MC, Plewka M, Gregori D, et al. Use of medical resources and quality of life of patients with chronic heart failure: a prospective survey in a large Italian community hospital. Eur J Heart Fail 1999; 1: 411-7
7. Sinagra GF, Perkan A, Zecchin M, et al. L'epidemiologia dello scompenso cardiaco: un problema crescente di sanità pubblica. G Ital Cardiol 1995; 25: 1043-53
8. Senni M, Gavazzi A. How patients with heart failure are managed in Italy. Eur J Heart Fail 2001; 3: 257-60
9. Berry C, Murdoch DR, McMurray JJV. Review article. Economics of chronic heart failure. Eur J Heart Fail 2000; 2: 283-91
10. Ambrosio GB, Riva LM, Zamboni S, et al. Lo scompenso di cuore nella popolazione: dati di prevalenza. Cardiologia 1992; 37: 235-9
11. Linné AB, Liedholm H, Jendteg S, Israelsson B. Health care costs of heart failure: results from a randomised study of patient education. Eur Heart J 2000; 2: 291-7
12. Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998; 19 (suppl P): P3-P39
13. Picenni A, Cocci A, Monina G, et al. Epidemiologia della cronicità cardiovascolare. Una proposta metodologica generale della SIFO-Lombardia. Giornale Italiano di Farmacia Clinica 2000; 4(1): 16-20
14. Bellotti P, Padano LP, Acquarone N, et al. Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR Study. Eur Heart J 2001; 22: 596-604
15. Working Group: Heart Failure. Italian network on outpatients with heart failure (IN-CHF). ANMCO - Italian Association of Hospital Cardiologists. Research activities year 2000
16. Simpson K, Blair J. Lisinopril. A review of its use in congestive heart failure. Drugs 2000; 59(5): 1149-67
17. Massie BM, Armstrong PW, Cleland JGF, et al. Toleration of high doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. Results from the ATLAS Study. Arch Intern Med 2001; 161: 165-71
18. Andersson F, Cline C, Rydén-Bergsten T, et al. Angiotensin converting enzyme (ACE) inhibitors and heart failure: the consequences of underprescribing. Pharmacoeconomics 1999; 15(6): 535-50
19. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-18
20. Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-69
21. Langtry HD, Markham A. Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997; 10: 131-66
22. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity; the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6
23. Goa KL, Haria M, Wilde MI. Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997; 53: 1081-105
24. Goa KL, Balfour JA, Zuanetti G. Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52: 564-88
25. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115-22
26. Agardh CD, Garcia-Puig J, Charbonnel S, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-92
27. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92
28. Chatuvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31
29. Franzosi MG, Maggioni AP, Santoro E, et al. Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction: Results from GISSI-3 trial. Pharmacoeconomics 1998; 13: 337-46.
30. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 333: 1670-6
31. Uretsky BF, Shaver JA, Liang CS, et al. Modulation of hemodynamic effects with converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observation on long-term clinical, functional and biochemical responses. Am Heart J 1988; 116: 480-8
32. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-35
33. The SOLVD Investigators. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 292-302
34. Katz DA, Welch HG. Discounting in cost-effectiveness analysis of Healthcare Programmes. Pharmacoeconomics 1993; 3(4): 276-85
35. Sculpher MJ, Poole L, Cleland JGF, et al. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the assessment of treatment with lisinopril and survival (ATLAS) study. Eur J Heart Fail 2000; 2: 447-454
36. Informatore Farmaceutico. Italian Directory of Medicines and Manufacturers, no 60. Milano: OEMF, 2001
37. Mason J, Young P, Freemantle N, Hobbs R. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. BMJ 2000; 321: 1113-6
38. Decreto Ministeriale 22/07/96. "Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe". Supplemento ordinario alla Gazzetta Ufficiale n. 216, 14/09/1996
39. Decreto Ministeriale 14/12/1994. "Tariffe, delle prestazioni di assistenza ospedaliera". Supplemento ordinario alla Gazzetta Ufficiale n. 209, 08/09/1997
40. Cleland JGF. Causes of death in the ATLAS study: effects of high-dose ACE-inhibitors. Intern J Clin Pract 1999; suppl 100: 19-20